{"id":43324,"date":"2026-02-17T14:00:00","date_gmt":"2026-02-17T14:00:00","guid":{"rendered":"http:\/\/www.prnasia.com\/story\/archive\/4889066_AE89066_0"},"modified":"2026-02-17T14:00:00","modified_gmt":"2026-02-17T14:00:00","slug":"metabolons-metabolomics-platform-enables-largest-metabolomic-analysis-to-date-in-car-t-cell-therapy-revealing-new-insights-into-severe-neurotoxicity","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=43324","title":{"rendered":"Metabolon’s Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity"},"content":{"rendered":"
\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Metabolomics-Derived Pathway Scores Outperform Inflammatory Protein Markers\u2014Delivering Risk Prediction Where Proteomics Falls Short<\/i><\/p>\n

MORRISVILLE, N.C.<\/span>, Feb. 17, 2026<\/span> \/PRNewswire\/ — Metabolon<\/a>, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced its industry-leading global metabolomics platform was used by researchers from Kite, a Gilead company, for the most extensive metabolomic study<\/a> ever conducted in the context of CAR T-cell therapy. Leveraging Metabolon’s untargeted Global Discovery Panel, Kite researchers analyzed more than 3,800 longitudinal serum and plasma samples\u2014and a rare set of cerebrospinal fluid (CSF) samples\u2014from patients treated with the FDA-approved anti-CD19 CAR T-cell therapies axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel).<\/p>\n

The multi-trial meta-cohort, spanning six clinical studies, enabled investigators to uncover metabolic pathways strongly associated with severe neurological events (NEs), a significant and sometimes life-threatening toxicity of CAR T-cell therapy. Despite the transformative efficacy of CAR T-cell treatments for large B-cell lymphoma (LBCL), mantle cell lymphoma, follicular lymphoma, and B-cell acute lymphoblastic leukemia, the biological drivers of neurotoxicity have remained poorly understood.<\/p>\n

"This study demonstrates how metabolomics uniquely exposes the biological pathways driving CAR T-cell\u2013associated neurotoxicity, insights that are not accessible through proteomics or cytokine profiling alone," said Heino Heyman<\/b>, <\/b>Director of Global Field Metabolomics Sciences at Metabolon. "By mapping disruptions in tryptophan catabolism, NMDA-linked excitotoxicity, and polyamine metabolism, the analysis not only identified patients at risk for severe neurologic events but also highlighted actionable pathway targets to mitigate toxicity. These findings demonstrate that metabolomics provides a functional, pathway-level understanding of safety and patient response, which is crucial for enhancing cell therapy design, monitoring strategies, and clinical outcomes."<\/p>\n

Using Metabolon’s high-resolution metabolomics platform, researchers identified clear and reproducible metabolic signatures that distinguished patients who developed high-grade NEs (grade \u2265 3). Notable findings include:<\/p>\n